Journal of the American Heart Association

MARCH 7, 2025

BackgroundCardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life. for Nterminal proBtype natriuretic peptide) while improving exercise parameters (improved placebocorrected peak oxygen consumption of at least 1.4

Cardiomyopathy 45

Cardiomyopathy Quality of Life Atrial Fibrillation Pharmacology 45

European Journal of Heart Failure

SEPTEMBER 26, 2023

Exercise training in patients with advanced heart failure and left ventricular assist device (Ex-VAD) trial. 6MWT, 6-min walk test; KCCQ, Kansas City Cardiomyopathy Questionnaire physical domain score; peakVO 2 , peak oxygen consumption; RCT, randomized controlled trial. m (95% CI 16.9, p  = 0.0124), both after 12 weeks. m (95% CI 16.9,

Exercise 40

Exercise Heart Failure Quality of Life Cardiomyopathy 40

Circulation

NOVEMBER 11, 2023

Background:Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight. mg or placebo for 52 weeks.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 40

American College of Cardiology

SEPTEMBER 30, 2024

Treatment with aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) was associated with broad clinical efficacy across multiple outcome domains, including rapid and sustained decreases in outflow gradients, meaningful improvements in functional class and quality of life, enhanced exercise capacity, and significant reductions in (..)

Quality of Life 40

Quality of Life Exercise Cardiomyopathy Outcomes 40

DAIC

MARCH 25, 2025

Efficacy of finerenone according to left atrial size in patients with heart failure and mildly reduced or preserved ejection fraction: An analysis of the FINEARTS-HF trial during the session " Finerenone: A Promising Addition to the Armamentarium or Merely an Academic Exercise?"

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

DAIC

APRIL 9, 2024

Decline in exercise ability is a hallmark of progression to overt heart failure. The international ARISE-HF trial was designed to test the effectiveness of the investigational drug AT-001 at stabilizing exercise capacity in patients with diabetic cardiomyopathy.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

Circulation

NOVEMBER 17, 2024

Primary endpoints: tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score(KCCQ-CSS). n=393) were female; BMI 38.26.7kg/m2, KCCQ-CSS 53.518.5,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Quality of Life 40

European Journal of Heart Failure

NOVEMBER 11, 2024

The main secondary study endpoints are all-cause mortality, cardiovascular mortality, incidence of implantable cardioverter-defibrillator (ICD) therapy, hospitalizations, quality of life, time to first ICD therapy, number of device-detected ventricular tachycardia/ventricular fibrillation episodes, left ventricular function, and exercise tolerance.

Heart Transplant 40

Heart Transplant Transplant Heart Failure Ablation 40

European Journal of Heart Failure

DECEMBER 7, 2023

Patients with increasing obesity have higher right- and left-sided ventricular filling pressures, increased cardiac output (CO), lower 6-min walk distance (6MWD) and worse Kansas City Cardiomyopathy Questionnaire (KCCQ) scores. Pulmonary vascular resistance at rest and exercise decreased with higher BMI. Overall, 60.9% Overall, 60.9%

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

Dr. Sanjay Gupta

MARCH 6, 2022

The heart hasn’t failed – it just doesn’t match up to the body’s requirements especially when the requirements are increased such as during exercise. Heart failure or cardiac insufficiency has marked negative effects both on quality of life and quantity of life. Thank you for reading.

Heart Failure 40

Heart Failure Quality of Life ACE Inhibitor Exercise 40

Dr. Sanjay Gupta

MAY 23, 2022

Today’s vlog is on the subject of heart failure and in particular on a special type of pacemaker which can make a significant improvement to the quality of life and length of life in patients with heart failure. length of life? You can download this script as a Hindi translation here. What is heart failure?

Heart Failure 40

Heart Failure Pacemaker Quality of Life ACE Inhibitor 40

Dr. Sanjay Gupta

MARCH 6, 2022

Pharmacological treatments: These can be divided into 2 groups Medications that improve quality of life (usually by relieving symptoms) and medications that can prolong life. Medications that improve quality of life in heart failure for example include diuretics. I hope you found this useful.

Chronic Disease 40

Chronic Disease Quality of Life Heart Failure Nursing 40

Heart BMJ

NOVEMBER 25, 2024

Regular physical activity combined with structured exercise training has well described benefits for quality of life and mortality in a range of cardiovascular conditions. For individuals with underlying genetic cardiac myopathies there has been concern that exercise training could trigger a potentially fatal event.

Exercise 52

Exercise Cardiomyopathy Quality of Life Congenital 52